Begin main content

Triple Therapy for Hepatitis C in Previous Non-responders: A Review of the Clinical Effectiveness and Safety

Published on: December 8, 2014
Project Number: RC0613-000
Product Line: Rapid Response
Research Type: Drug
Report Type: Summary with Critical Appraisal
Result type: Report

Question

  1. What is the clinical effectiveness and safety of simeprevir and/or sofosbuvir combined with peginterferon + ribavirin (PR) in patients with chronic hepatitis C genotype 1 who have had an inadequate response to prior direct acting antiviral (DAA) plus (PR) therapy or prior treatment with PR alone?
  2. What is the clinical effectiveness and safety of simeprevir and/or sofosbuvir and PR combination treatments in patients with chronic hepatitis C genotype 2 who have had an inadequate response to prior DAA plus PR therapy or prior treatment with PR alone?
  3. What is the clinical effectiveness and safety of simeprevir and/or sofosbuvir and PR combination treatments in patients with chronic hepatitis C genotype 3 who have had an inadequate response to prior DAA plus PR therapy or prior treatment with PR alone?
  4. What is the clinical effectiveness and safety of simeprevir and/or sofosbuvir and PR combination treatments in patients with chronic hepatitis C genotype 4 who have had an inadequate response to prior DAA plus PR therapy or prior treatment with PR alone?

Key Message

In general, findings from the included studies were consistent on the superiority of simeprevir once daily plus PR therapy to placebo plus PR therapy in terms of SVR in patients with chronic hepatitis C genotype 1 who have had an inadequate response to prior PR therapy. The addition of simeprevir to PR was well tolerated generally, with comparable adverse events rates compared to PR alone. The literature search did not identify evidence on sofosbuvir. There was a lack of evidence on patients with HCV genotypes 2, 3 or 4.

Tags

ribavirin, rebetol, hepacivirus, hepatitis c, hepatitis, simeprevir, sofosbuvir, peginterferon, pegylated interferon, Galexos, Olysio, Sovaldi, Copegus, Pegasys, Hep C, HCV, Chronic, Interferon Alfa-2a